Lena Seidemann
Overview
Explore the profile of Lena Seidemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kronert N, Moulla Y, Lange U, Bluher M, Linder N, Fuhrmann A, et al.
Langenbecks Arch Surg
. 2025 Jan;
410(1):36.
PMID: 39804512
Purpose: Obesity and type 2 diabetes (T2DM) are major risk factors for hepatic steatosis. Diet or bariatric surgery can reduce liver volume, fat content, and inflammation. However, little is known...
2.
Zimmermann A, Scheffschick A, Hansel R, Borchardt H, Liu J, Ehnert S, et al.
Arch Toxicol
. 2024 Dec;
99(3):1167-1185.
PMID: 39710784
The development of in vitro hepatocyte cell culture systems is crucial for investigating drug-induced liver injury (DILI). One prerequisite for monitoring DILI related immunologic reactions is the extension of primary...
3.
Seidemann L, Lippold C, Rohm C, Eckel J, Schicht G, Matz-Soja M, et al.
BMC Endocr Disord
. 2024 Aug;
24(1):135.
PMID: 39090659
Background: Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is higher in men than in women. Hormonal and genetic causes may account for the sex differences in MASLD. Current human...
4.
Forberger M, Seidemann L, Trawinski H, Blaker H, von Laffert M
Pathologie (Heidelb)
. 2023 Oct;
45(1):1.
PMID: 37861700
No abstract available.
5.
Moulla Y, Hamadeh H, Seidemann L, Mehdorn M, Bluher M, Feisthammel J, et al.
Obes Surg
. 2023 Sep;
33(11):3391-3401.
PMID: 37776419
Introduction: Morbid obesity is well known as a risk factor for gastroesophageal reflux disease (GERD) and its related disorders such as Barrett's esophagus (BE). This study aimed to evaluate the...
6.
Seidemann L, Dietrich A
J Med Case Rep
. 2023 Sep;
17(1):379.
PMID: 37667406
Background: Bariatric surgery candidates commonly suffer from conditions that constitute the metabolic syndrome. But they also have a higher risk for autoimmune and malignant diseases. Obesity-associated comorbidities aside from the...
7.
Seidemann L, Moulla Y, Dietrich A
Chirurgie (Heidelb)
. 2023 Mar;
94(6):506-511.
PMID: 36894649
Background: Intestinal bypass procedures are well recognized for their long-term weight reduction and control of metabolic comorbidities. The selection of the length of the small bowel loop has a significant...
8.
Seidemann L, Prinz S, Scherbel J, Gotz C, Seehofer D, Damm G
EXCLI J
. 2023 Jan;
22:12-34.
PMID: 36660192
Loss of differentiation of primary human hepatocytes (PHHs) is a known problem of liver models. Culture optimizations using collagen type I and Matrigel reduce the dedifferentiation process but are not...
9.
Schicht G, Seidemann L, Haensel R, Seehofer D, Damm G
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077764
Metabolic alterations in hepatocellular carcinoma (HCC) are fundamental for the development of diagnostic screening and therapeutic intervention since energy metabolism plays a central role in differentiated hepatocytes. In HCC research,...
10.
Seidemann L, Kruger A, Kegel-Hubner V, Seehofer D, Damm G
Molecules
. 2021 Mar;
26(4).
PMID: 33671486
Nonalcoholic fatty liver disease (NAFLD) is among the leading causes of end-stage liver disease. The impaired hepatic lipid metabolism in NAFLD is exhibited by dysregulated PPARα and SREBP-1c signaling pathways,...